Vir Biotechnology, Inc. (Nasdaq: VIR), today announced a collaboration and license agreement with Gilead to discover and engineer three novel PRO-XTEN® dual-masked T-cell engager (TCE) development ...

Vir Biotechnology ( ($VIR) ) has provided an update. On October 9, 2026, Vir Biotechnology entered a collaboration and license agreement with Gilead Sciences to ...

The Defense Innovation Networking Group (D!NG) today announced that the submission window is officially open for the ...

Biotechnology is a broad discipline in which biological processes, organisms, cells or cellular components are exploited to develop new technologies. New tools and products developed by ...

Sana Biotechnology trades at a steep discount despite promising T1D assets UP421 and SC451. Check out why SANA stock is a buy ...

The Invesco Biotechnology & Genome ETF (PBE) made its debut on 06/23/2005, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market. What ...

Vir Biotechnology is now a two-engine company, with major pharma partnerships and a fully enrolled hepatitis delta phase 3 program. See why VIR stock is a buy.

Vir Biotechnology has appointed Aziz Sawaf as Executive Vice President and Chief Financial Officer, effective October 5, 2026 ...

Launched on June 23, 2005, the Invesco Biotechnology & Genome ETF (PBE) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the ...

FHLC offers broader sector exposure at a 0.08% expense ratio, compared with IBB's concentrated biotech focus at 0.44%, but ...

Researchers identify GmRVE4d as a gene that delays soybean flowering and maturity by repressing GmPRR5a. This finding highlights GmRVE4d as a potential breeding target for improving soybean adaptation ...